00:00So when we were at this conference last year, I believe you were days on the job as CEO.
00:06So talk us through what year one was like and what is your focus as we head deeper into 2026?
00:11Sure. And again, thanks for having me again. And you're not wrong. I believe it was day six last year when I met with you.
00:17So it was a busy first week. You know, the first year was focused on what I think many new CEOs focus on,
00:23which is kind of starting with talent and making sure that you accurately understand what your business is conveying
00:28from a vision and mission perspective, but quickly was able to jump into some key strategic priorities.
00:34And interestingly, those have largely remained the same as we roll into 26.
00:38So those four things largely continue to be partnering with manufacturers around bringing those branded point of sale
00:45and affordability programs to the market, continues to be integrated and focusing with retail pharmacies,
00:51whereby we are fixated on the consumer experience and ensuring that we reduce friction at the counter.
00:56And a corollary to that is also ensuring that margin is favorable for those same pharmacies.
01:02It continues to be advocating and benefiting HCPs who are prescribing drugs such that we continue to be that number one referred brand app that folks are using.
01:13And a slight nuance maybe compared to 2025.
01:15We had mentioned it last year, but we're just now affecting it in reality, is we are focused on employers such that that discount pricing that we're conveying,
01:25we're now making it easier for employers to avail themselves of it, too, to convey to their employees.
01:31I believe I'd mentioned it last year, but we hadn't actively started partnering and we're actively investing and working on that in 2026.
01:37Well, another nuance between this year and last year is that the Trump administration planning a new website called TrumpRx.
01:44The idea here is that people would buy their prescription drugs directly from manufacturers.
01:50And I'm wondering, you know, how you're factoring that in, how that might potentially affect GoodRx's business going forward.
01:56Now, I appreciate the question.
01:58I will tell you, last year at this point, I didn't know that anyone could have predicted the busy regulatory environment that turned out to be 2025.
02:05Right.
02:06And, you know, certainly I think from an investor perspective, we've had a lot of questions on TrumpRx and there's been a lot of confusion as to what it means.
02:12But at the end of the day, TrumpRx is going to be a repository for MFN pricing for brand drugs,
02:19of which GoodRx is the number one partner for pharma to do these deals with.
02:24So we are actively integrated.
02:26We will be powering a significant component of TrumpRx.
02:30Whenever they decide to launch, that is going to be their story to tell.
02:34But what we do know is, look, policy is important and we're thrilled that this administration is leaning into reducing the cost of these same drugs.
02:42But policy only gets you so far.
02:45You've actually got to activate that pricing and pharma needs a network through which they can convey that same pricing.
02:51We are that turnkey solution for pharma.
02:53We already had been.
02:54But I will also give this administration credit for fueling some manufacturers who may have been on the fence on doing a D2P deal.
03:02And as they're doing that, they're looking to us to partner to convey that through the TrumpRx platform as well.
03:08So we're thankful for that fuel.
03:10Interesting.
03:10So just to, you know, put a bow on that point, it sounds like you're not necessarily competing there, but integrated into TrumpRx.
03:18That's correct.
03:18TrumpRx is not actively selling drugs.
03:21They're not a pharmacy.
03:24They need to work with partners to convey that pricing to Americans who wish to avail themselves of it.
03:28And let's talk a little bit about news that came out during this conference, partnering with SureScript.
03:33Talk us through, you know, what this partnership you're hoping will bear.
03:37Sure.
03:38Sure.
03:39I would be remiss without saying it's been a year in the making.
03:41We were actually thinking about this when I was here last year at this time.
03:45And given my broader health care background, I have long held a vision for having cash and funded pricing sit side by side.
03:53That's much easier said than done, obviously.
03:56The manner in which you find cash pricing can be pretty haphazard at times.
04:01The partnership with SureScripts is one in which it's a web-enabled, mobile-friendly price point that will convey to you at the time of prescribing.
04:11So think about if you're sitting in a physician's office, your physician prescribes whatever it is they need to prescribe for you,
04:18you will automatically be given a secure text link to opt into seeing the comparison that is GoodRx pricing to your funded price
04:27in addition to other affordability programs that a manufacturer may offer for that particular drug.
04:32And when you think about the exclusive GoodRx discount participation partnership embedded in that,
04:39we are the only partner that also can connect that pricing to literally every pharmacy in the U.S.
04:45So it will provide you and I the opportunity to look side by side at that pricing, make the decision that is best for you,
04:52and choose the pharmacy that is best for you.
04:54And if you step back from it, it's really about moving that affordability opportunity closer and upper in the funnel
05:01as you think about the whole prescription journey.
05:04Over time, this really has the opportunity to transform how we contemplate cash sitting right adjacent to
05:10and as a complement to insurance.
05:12It will be rolling out as we speak in Texas and Illinois.
05:16And in partnership with SureScripts, it will eventually over time grow across additional states and through additional prescribers.
Be the first to comment